Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

News Daily News

Regaining Weight Won’t Erode CV Risk Factor Benefits Short Term

L.A. McKeown

March 31, 2023

News Conference News ESC 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

Michael O'Riordan

August 29, 2022

News Daily News

Good News and Bad for High-Intensity Statin Use in ASCVD

Michael O'Riordan

May 05, 2022

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

News Daily News

Could an App Replace Statin Prescribing by Doctors?

Michael O'Riordan

September 08, 2021

News Daily News

Cholesterol Guidelines Fail Young MI Patients Who Might Have Benefited From Statins

L.A. McKeown

August 04, 2020

ORION-11: Inclisiran Shows Promise, Safety in Largest Published Cohort

News Conference News ESC 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Yael L. Maxwell

September 03, 2019

News Conference News ESC 2019

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

Michael O'Riordan

September 02, 2019

News Conference News ESC 2019

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Yael L. Maxwell

August 31, 2019

News Daily News

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Michael O'Riordan

July 19, 2019

News Daily News

Bias Over Knowledge: Whether Patients Get Guideline-Recommended Statins Depends on Physician Beliefs

Yael L. Maxwell

January 10, 2019

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Shelley Wood

November 05, 2018

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Shelley Wood

October 22, 2018

News Conference News TCT 2018

Statin Preloading Benefit More Pronounced in STEMI Patients: SECURE-PCI

Michael O'Riordan

October 05, 2018

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

News Conference News AHA 2016

Racial Differences in How Patients Perceive CVD Risk Should Spur Rethink in Management

Yael L. Maxwell

November 16, 2016

News Daily News

More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds

Yael L. Maxwell

August 29, 2016

News Daily News

The EU Versus US Lipid Guideline Debate: It’s the Gap That Matters, Experts Say

Shelley Wood

July 19, 2016

News Conference News AHA 2015

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Todd Neale

November 12, 2015

Advertisement

Regaining Weight Won’t Erode CV Risk Factor Benefits Short Term

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

Good News and Bad for High-Intensity Statin Use in ASCVD

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Could an App Replace Statin Prescribing by Doctors?

Cholesterol Guidelines Fail Young MI Patients Who Might Have Benefited From Statins

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Bias Over Knowledge: Whether Patients Get Guideline-Recommended Statins Depends on Physician Beliefs

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Statin Preloading Benefit More Pronounced in STEMI Patients: SECURE-PCI

Evolocumab Not Cost-Effective at Current List Price

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Racial Differences in How Patients Perceive CVD Risk Should Spur Rethink in Management

More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds

The EU Versus US Lipid Guideline Debate: It’s the Gap That Matters, Experts Say

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content